Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis Neuroscience

Understanding the mode of action of drugs is a challenge with conventional methods in clinical trials. Here, we aimed to explore whether simvastatin effects on brain atrophy and disability in secondary progressive multiple sclerosis (SPMS) are mediated by reducing cholesterol or are independent of cholesterol. We applied structural equation models...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: PNAS Plus Source Type: research

Related Links:

In conclusion, the study indicates that HBOT may induce significant senolytic effects that include significantly increasing telomere length and clearance of senescent cells in the aging populations. Data on the Prevalence of Liver Fibrosis in Middle Age https://www.fightaging.org/archives/2020/11/data-on-the-prevalence-of-liver-fibrosis-in-middle-age/ Fibrosis is a consequence of age-related disarray in tissue maintenance processes, leading to the deposition of scar-like collagen that disrupts tissue structure and function. It is an ultimately fatal issue for which there are only poor treatment options a...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
We present normally distributed variables using means and standard deviations and non-normally distributed variables using medians along with their ranges. Spearman's correlation coefficients were used to analyse correlations between the CSF's biomarker concentrations, and both unadjusted and Bonferroni adjusted p-values are reported. Orthogonal projection to latent structure discriminant analysis (OPLS-DA) was also used to find differences in terms of CSF metabolites between the relapsing and remitting patients [CIS, RR, PR versus PP, SP patients]. The OPLS-DA algorithm finds the projection direction, score vector, that g...
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
In this study, we found that cofilin competes with tau for direct microtubule binding in vitro, in cells, and in vivo, which inhibits tau-induced microtubule assembly. Genetic reduction of cofilin mitigates tauopathy and synaptic defects in Tau-P301S mice and movement deficits in tau transgenic C. elegans. The pathogenic effects of cofilin are selectively mediated by activated cofilin, as active but not inactive cofilin selectively interacts with tubulin, destabilizes microtubules, and promotes tauopathy. These results therefore indicate that activated cofilin plays an essential intermediary role in neurotoxic signaling th...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
This study shows that mRNA levels of the aging related lamin A splice variant progerin, associated with premature aging in HGPS, were significantly upregulated in subjects with BMI ≥ 25 kg/m2. Moreover, our data revealed a significantly positive correlation of BMI with progerin mRNA. These data provide to our knowledge for the first-time evidence for a possible involvement of progerin in previously observed accelerated aging of overweight and obese individuals potentially limiting their longevity. Our results also showed that progerin mRNA was positively correlated with C-reactive protein (CRP). This might suggest an as...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Trial involving almost 1,200 people aims to ‘establish definitively’ whether cholesterol drug can slow disability progressionScientists are hopeful a major drug trial will establish that statins can be used to treat multiple sclerosis.The low-cost drugs are typically prescribed to help lower levels of “bad cholesterol” associated with raised risk of a heart attack or stroke, but they have also shown “incredible promise” for the treatment of MS.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Multiple sclerosis Statins Medical research NHS Society Health Science UK news Source Type: news
Objective:To further characterise lipid biomarkers in the metabolomic profiles of multiple sclerosis (MS) patients.Background:Associations between the clinical stage of MS and circulating lipoprotein-bound cholesterol have been reported (Dickens et al. 2014). A recent phase II clinical trial (Chataway et al. 2014) showing efficacy of simvastatin in treating secondary progressive MS suggests that lipid dysregulation may contribute to progression of disability.Design/Methods:Plasma samples from 27 patients with relapsing-remitting MS (12M, 15F, mean age 41.7±12.5, median EDSS 1.5 (range 1.0–7.0)), treatment free...
Source: Neurology - Category: Neurology Authors: Tags: Biomarkers and Experimental Studies for Multiple Sclerosis II Source Type: research
Conclusions: Our results suggest that the combination of atorvastatin and interferon β1b is not justified in early relapsing–remitting multiple sclerosis and adds to the body of evidence indicating an absence of significant radiological and clinical benefit of statins in relapsing–remitting multiple sclerosis.
Source: Multiple Sclerosis - Category: Neurology Authors: Tags: Original Research Papers Source Type: research
This study teaches us that poor wound healing and wrinkling and sagging that occur in aging skin share similar mechanisms." Reduced cell cohesiveness of outgrowths from eccrine sweat glands delays wound closure in elderly skin Human skin heals more slowly in aged vs. young adults, but the mechanism for this delay is unclear. In humans, eccrine sweat glands (ESGs) and hair follicles underlying wounds generate cohesive keratinocyte outgrowths that expand to form the new epidermis. Our results confirm that the outgrowth of cells from ESGs is a major feature of repair in young skin. Strikingly, in aged s...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Academies | Brain | Cholesterol | Clinical Trials | Disability | Multiple Sclerosis | Neurology | Science | Simvastatin | Statin Therapy | Zocor